AU2003266881A1 - Process for differential diagnosis of alzheimer's dementia in patients exhibiting mild cognitive impairment - Google Patents

Process for differential diagnosis of alzheimer's dementia in patients exhibiting mild cognitive impairment Download PDF

Info

Publication number
AU2003266881A1
AU2003266881A1 AU2003266881A AU2003266881A AU2003266881A1 AU 2003266881 A1 AU2003266881 A1 AU 2003266881A1 AU 2003266881 A AU2003266881 A AU 2003266881A AU 2003266881 A AU2003266881 A AU 2003266881A AU 2003266881 A1 AU2003266881 A1 AU 2003266881A1
Authority
AU
Australia
Prior art keywords
antibody
dementia
alzheimer
assay
atcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003266881A
Other languages
English (en)
Inventor
George Jackowski
Miyoko Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn X Pharma Inc
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Publication of AU2003266881A1 publication Critical patent/AU2003266881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003266881A 2002-09-17 2003-09-16 Process for differential diagnosis of alzheimer's dementia in patients exhibiting mild cognitive impairment Abandoned AU2003266881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/246,383 2002-09-17
US10/246,383 US7070945B2 (en) 2001-04-25 2002-09-17 Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
PCT/CA2003/001403 WO2004027429A1 (en) 2002-09-17 2003-09-16 Process for differential diagnosis of alzheimer's dementia in patients exhibiting mild cognitive impairment

Publications (1)

Publication Number Publication Date
AU2003266881A1 true AU2003266881A1 (en) 2004-04-08

Family

ID=32028955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003266881A Abandoned AU2003266881A1 (en) 2002-09-17 2003-09-16 Process for differential diagnosis of alzheimer's dementia in patients exhibiting mild cognitive impairment

Country Status (7)

Country Link
US (1) US7070945B2 (ja)
EP (1) EP1540349A1 (ja)
JP (1) JP2005539228A (ja)
AU (1) AU2003266881A1 (ja)
CA (1) CA2498881A1 (ja)
NZ (1) NZ538669A (ja)
WO (1) WO2004027429A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP1692520A2 (en) * 2003-11-19 2006-08-23 Satoris, Inc. Method for diagnosis, stratification and monitoring of alzheimer's disease
US20060099624A1 (en) * 2004-10-18 2006-05-11 Wang Lu-Yong System and method for providing personalized healthcare for alzheimer's disease
US9086408B2 (en) 2007-04-30 2015-07-21 Nexus Dx, Inc. Multianalyte assay
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
CA2778339A1 (en) 2008-11-07 2010-05-14 Department Of Biotechnology A ready automated screening, diagnosis & classification technique for alzheimer's disease using magnetic resonance imaging signal from ventricular zone contour of brain
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
EP2743696A4 (en) * 2011-08-11 2015-04-29 Otsuka Pharma Co Ltd METHOD OF PRETREATING A BIOLOGICAL SAMPLE CONTAINING A PROTEIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445937A (en) 1991-12-24 1995-08-29 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using an improved photoaffinity labeling method
EP0625212B1 (en) 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor

Also Published As

Publication number Publication date
WO2004027429A1 (en) 2004-04-01
CA2498881A1 (en) 2004-04-01
US20030064416A1 (en) 2003-04-03
JP2005539228A (ja) 2005-12-22
NZ538669A (en) 2007-01-26
US7070945B2 (en) 2006-07-04
EP1540349A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
US6451547B1 (en) Process for differential diagnosis of Alzheimer's dementia and device therefor
Ghanbari et al. Biochemical assay for AD7C‐NTP in urine as an Alzheimer's disease marker
JP7492711B2 (ja) アルツハイマー病バイオマーカー
US20120052592A9 (en) Method for determining prognosis of acute central nervous system disorder
JP2017504808A (ja) アルツハイマー病の早期診断のためのバイオマーカーおよび方法
US7070945B2 (en) Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
US20030119074A1 (en) Diagnosis and treatment of dementia utilizing thrombospondin
KR20200047371A (ko) 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커
AU2002252888A1 (en) Process for differential diagnosis of alzheimer's dementia and device therefor
KR102478021B1 (ko) 혈장을 이용한 알츠하이머병의 진단
KR101305515B1 (ko) 펜트락신 3 단백질의 파킨슨 질환 진단 용도
US20220308073A1 (en) Biomarker for alzheimer's disease
JP4264469B2 (ja) 痴呆症の検査方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period